检验医学 ›› 2013, Vol. 28 ›› Issue (9): 811-814.DOI: 10.3969/j.issn.1673-8640.2013.09.019

• 临床应用研究.论著 • 上一篇    下一篇

慢性乙型肝炎患者外周血CD4+CD25+ Foxp3+调节性T细胞变化水平及其与抗病毒疗效的关系

卿克勤1,杨朝国2,刘蓉2   

  1. 1.成都市第一人民医院, 四川成都610041;
    2.成都中医药大学医学技术学院, 四川成都611137
  • 收稿日期:2012-07-09 修回日期:2013-09-25 出版日期:2013-09-15 发布日期:2013-09-25
  • 通讯作者: 杨朝国,联系电话:028-86137273。
  • 作者简介:卿克勤,男,1966年生,副主任技师,主要从事临床免疫学检验工作。

Analysis on the change of CD4CD25Foxp3 regulatory T cells in peripheral blood of patients with chronic hepatitis B

QING Keqin1,YANG Chaoguo2,LIU Rong2   

  1. 1.The First People′s Hospital of Chengdu,Sichuan Chengdu 610041,China;
    2.School of Medicine,Chengdu University of Traditional Chinese Medicine,Sichuan Chengdu 611137,China
  • Received:2012-07-09 Revised:2013-09-25 Online:2013-09-15 Published:2013-09-25

摘要:

目的 了解慢性乙型肝炎(CHB)患者外周血CD4+CD25+Foxp3+调节性T细胞(Treg)水平及其在乙型肝炎病毒(HBV)感染中的作用。方法 采用流式细胞仪检测86例CHB患者、30名急性乙型肝炎(AHB)患者和30例健康体检者外周血CD4+CD25+Foxp3+Treg频率,分析HBV DNA载量与CD4+CD25+Foxp3+Treg频率的关系及治疗后不同疗效的CD4+CD25+Foxp3+Treg频率,并对轻度、中度和重度CHB患者的CD4+CD25+Foxp3+Treg频率进行比较。结果 CHB组外周血CD4+CD25+Foxp3+Treg占CD4T细胞的百分比为2.56%±1.12%,明显高于AHB组(1.39%±0.68%)和正常对照组(1.45%±0.76%)(P<0.05),而AHB组与正常对照组之间差异无统计学意义(P>0.05)。轻度、中度和重度活动性CHB各组之间外周血CD4+CD25+Foxp3+Treg频率差异均无统计学意义(P>0.05)。CHB组、AHB组外周血ALT水平分别为285.6±168.3、(780.9±432.6)U/L,均明显高于正常对照组[(23.2±6.7)U/L](P<0.05),CHB组低于AHB组(P<0.05)。CHB患者外周血CD4+CD25+Foxp3+Treg频率与ALT水平无相关性(r=0.11,P>0.05)。CHB组、AHB组和正常对照组外周血HBV DNA分别为(5.2±1.8)log10拷贝/mL、(7.2±1.8)log10拷贝/mL和阴性,AHB组明显高于CHB组(P<0.05)。CHB患者外周血CD4+CD25+Foxp3+Treg频率与HBV DNA的对数呈正相关(r=0.30,P<0.05)。经抗病毒治疗后,疗效明显的CHB患者外周血CD4+CD25+Foxp3+Treg频率下降,明显低于疗效不明显组(P<0.05)。结论 CD4+CD25+Foxp3+Treg升高可能是HBV感染慢性化的重要因素之一,调节CD4+CD25+Foxp3+Treg的数量和功能可能为治疗CHB提供一个新途径。

关键词: CD4CD25Foxp3调节性T细胞, 慢性乙型肝炎, 疗效

Abstract:

Objective To investigate the frequency of CD4+CD25+Foxp3+ regulatory T cells (Treg)in peripheral blood of patients with chronic hepatitis B (CHB)and its significance in the hepatitis B virus (HBV)infection. Methods The frequencies of CD4+CD25+Foxp3+Treg in peripheral blood from 86 CHB patients,30 acute hepatitis B (AHB)patients and 30 healthy subjects were determined by flow cytometry.The correlations of HBV DNA loads with CD4+CD25+Foxp3+ Treg frequency and the frequency of CD4+CD25+Foxp3+ Treg after therapy with different therapeutic effects were analyzed respectively.CD4+CD25+Foxp3+ Treg frequencies among mild,moderate and severe active CHB patients were compared respectively. Results The percentages of CD4+CD25+Foxp3+ Treg in CHB patients,AHB patients and healthy subjects were 2.56%±1.12%,1.39%±0.68% and 1.45%±0.76%, respectively.The percentage in CHB patients was higher than those in AHB patients and healthy subjects (P<0.05),and there was no statistical significance between the percentages of AHB patients and healthy subjects (P>0.05).The percentages of CD4+CD25+Foxp3+ Treg among mild,moderate and severe active CHB patients had no statistical significance (P>0.05).The levels of alanine aminotransferase (ALT)in CHB patients,AHB patients and healthy subjects were 285.6±168.3,(780.9±432.6) and (23.2±6.7) U/L, respectively.The levels of ALT in CHB patients and AHB patients were higher than that in healthy subjects(P<0.05).The level of ALT in CHB patients was lower than that in AHB patients(P<0.05).The frequency of CD4+CD25+Foxp3+ Treg was not correlated with the level of ALT (r=0.11,P>0.05).The HBV DNA loads in CHB patients,AHB patients and healthy subjects were (5.2±1.8)log10copies/mL,(7.2±1.8)log10copies/mL and negative respectively.The HBV DNA load in AHB patients was higher than that in CHB patients(P<0.05).There was a positive correlation between CD4+CD25+Foxp3+ Treg frequency and HBV DNA logarithm(r=0.30,P<0.05).CD4+CD25+Foxp3+ Treg frequency decreased obviously after anti-viral therapy in the patients with obvious good therapeutic effect,and it was lower than that in the patients with poor therapeutic effect (P<0.05). Conclusions The increase of CD4+CD25+Foxp3+ Treg in CHB patients plays an active role in chronic HBV.The regulation and control of function and amount of CD4+CD25+Foxp3+ Treg may provide a new therapy for CHB.

Key words: CD4+CD25+Foxp3+ regulatory T cell, Chronic hepatitis B, Therapeutic effect

中图分类号: